Australia-based Telix Pharmaceuticals inks oncology deal with Eli Lilly

[cafead]

via Australia's Telix Pharmaceuticals has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma (STS).

article source